Abstract EGFR, BRAF, PIK3CA, and KRAS genes play major roles in EGFR pathway, and
accommodate activating mutations that predict response to many targeted therapeutics …

Genes functioning in epidermal growth factor receptor (EGFR) signaling pathways are
among the most frequently activated oncogenes in human cancers. We have conducted a …

Melanoma is a highly malignant tumor of the skin melanocytes. Patients with this cancer
have a high frequency (~ 50%) of oncogenic BRAF mutations, particularly BRAF V600E …

This review article deals with the analysis and the detection of the morphological features
associated with somatic mutations, mostly BRAF V600E mutation, on both cytological and …

Abstract Background The BRAF V600E gene encodes for the mutant BRAF V600E protein,
which triggers downstream oncogenic signaling in thyroid cancer. Since most currently …

Background Comprehensive molecular diagnostics plays a key role in precision medicine
and is commonly used to screen for activating hotspot mutations, amplifications and gene …

Targeted therapy against epidermal growth factor receptor (EGFR) represents a major
therapeutic advance in lung cancer treatment. Somatic mutations of the EGFR gene, most …

Lung cancer is the leading cause of death for malignancy worldwide. Its molecular profiling
has enriched our understanding of cancer initiation and progression and has become …

Background Epidermal growth factor receptor (EGFR) and its downstream factors KRAS and
BRAF are mutated in several types of cancer, affecting the clinical response to EGFR …

Abstract Background Whereas 40% to 70% of papillary thyroid carcinomas (PTCs) are
characterized by a BRAF mutation (BRAF mut), unified biomarkers for the genetically …